ARQT
Arcutis Biotherapeutics
$31.45
−$0.23 (−0.73%)Oct 28, 2026
Key metrics
The numbers that frame ARQT today
- Market cap
- $3.95B
- P/E (TTM)
- 149.8
- EV / FCF
- 103.0
- Gross margin
- 91.1%
- EV / Sales
- 8.7
- ROIC
- 12%
- Div yield
- 0%
- Debt / equity
- 0.5
- 52wk Low
- $19.30
- 52wk High
- $33.30
Growth
Revenue and earnings trend for ARQT
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about ARQT
Is Arcutis Biotherapeutics a good buy?
Yes. Arcutis Biotherapeutics has strong quality and excellent momentum. Both signals support the setup. Growth looks excellent, which supports the long-term business case. We think Arcutis Biotherapeutics is selling at a high price, which cuts against the buy case.
What is the market capitalization of ARQT?
Arcutis Biotherapeutics's market capitalization is $3.95B.
What is the P/E (TTM) ratio for ARQT stock?
Arcutis Biotherapeutics's P/E (TTM) ratio is 149.8, based on trailing earnings.
What is the 52-week high for ARQT stock?
The 52-week high for Arcutis Biotherapeutics is $33.30. The current close of $31.45 is 5.6% below that high.
What is the 52-week low for ARQT stock?
The 52-week low for Arcutis Biotherapeutics is $19.30. The current close of $31.45 is 63% above that low.
Does ARQT stock pay dividends?
Arcutis Biotherapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for ARQT?
Arcutis Biotherapeutics's Debt / Equity ratio is 0.52.